SCOPUS 정보 검색 플랫폼

American Journal of Cardiology

Volumn 108, Issue 2, 2011, Pages 302-307

Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension

(5) Klinger, James R a Oudiz, Ronald J b Spence, Rebecca c Despain, Darrin c Dufton, Christopher c

a BROWN UNIVERSITY (United States)

b HARBOR UCLA MEDICAL CENTER (United States)

c GILEAD SCIENCES (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; PLACEBO;

ADULT; AGED; ANEMIA; ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DYSPNEA; EXERCISE; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART PALPITATION; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE FAILURE; HUMAN; LONG TERM CARE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NOSE CONGESTION; PERIPHERAL EDEMA; POST HOC ANALYSIS; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; WALKING;

ANTIHYPERTENSIVE AGENTS; ATRIAL FUNCTION, RIGHT; CARDIAC OUTPUT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHENYLPROPIONATES; PULMONARY WEDGE PRESSURE; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; VASCULAR RESISTANCE;

EID: 79959705233 PISSN: 00029149 EISSN: 18791913 Source Type: Journal
DOI: 10.1016/j.amjcard.2011.03.037 Document Type: Article

Times cited : (42)

References (12)

1
- 46449124591
- Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) study 1 and 2
- Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group
- N. Gali, H. Olschewski, R.J. Oudiz, F. Torres, A. Frost, H.A. Ghofrani, D.B. Badesch, M.D. McGoon, V.V. McLaughlin, E.B. Roecker, M.J. Gerber, C. Dufton, B.L. Wiens, L.J. Rubin Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) study 1 and 2 Circulation 117 2008 3010 3019
- (2008) Circulation , vol.117 , pp. 3010-3019
- Gali, N.¹ Olschewski, H.² Oudiz, R.J.³ Torres, F.⁴ Frost, A.⁵ Ghofrani, H.A.⁶ Badesch, D.B.⁷ McGoon, M.D.⁸ McLaughlin, V.V.⁹ Roecker, E.B.¹⁰ Gerber, M.J.¹¹ Dufton, C.¹² Wiens, B.L.¹³ Rubin, L.J.¹⁴

2
- 22844436819
- Ambrisentan therapy for pulmonary arterial hypertension
- DOI 10.1016/j.jacc.2005.04.050, PII S0735109705010478
- N. Galié, D. Badesch, R. Oudiz, G. Simonneau, M.D. McGoon, A.M. Keogh, A.E. Frost, D. Zwicke, R. Naeije, S. Shapiro, H. Olschewski, and L.J. Rubin Ambrisentan therapy for pulmonary arterial hypertension J Am Coll Cardiol 46 2005 529 535 (Pubitemid 41040298)
- (2005) Journal of the American College of Cardiology , vol.46 , Issue.3 , pp. 529-535
- Galie, N.¹ Badesch, D.² Oudiz, R.³ Simonneau, G.⁴ McGoon, M.D.⁵ Keogh, A.M.⁶ Frost, A.E.⁷ Zwicke, D.⁸ Naeije, R.⁹ Shapiro, S.¹⁰ Olschewski, H.¹¹ Rubin, L.J.¹²

3
- 70350708667
- Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension
- ARIES Study Group
- R.J. Oudiz, N. Gali, H. Olschewski, F. Torres, A. Frost, H.A. Ghofrani, D.B. Badesch, M.D. McGoon, V.V. McLaughlin, E.B. Roecker, B.C. Harrison, D. Despain, C. Dufton, L.J. Rubin ARIES Study Group Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension J Am Coll Cardiol 54 2009 1971 1981
- (2009) J Am Coll Cardiol , vol.54 , pp. 1971-1981
- Oudiz, R.J.¹ Gali, N.² Olschewski, H.³ Torres, F.⁴ Frost, A.⁵ Ghofrani, H.A.⁶ Badesch, D.B.⁷ McGoon, M.D.⁸ McLaughlin, V.V.⁹ Roecker, E.B.¹⁰ Harrison, B.C.¹¹ Despain, D.¹² Dufton, C.¹³ Rubin, L.J.¹⁴

4
- 0030031888
- A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
- The Primary Pulmonary Hypertension Study Group
- R.J. Barst, L.J. Rubin, W.A. Long, M.D. McGoon, S. Rich, D.B. Badesch, B.M. Groves, V.F. Tapson, R.C. Bourge, B.H. Brundage, S.K. Koerner, D. Langleben, C.A. Keller, S. Murali, B.F. Uretsky, L.M. Clayton, M.M. Jbsis, S.D. Blackburn Jr, D. Shortino, J.W. Crow The Primary Pulmonary Hypertension Study Group A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension N Engl J Med 334 1996 296 302
- (1996) N Engl J Med , vol.334 , pp. 296-302
- Barst, R.J.¹ Rubin, L.J.² Long, W.A.³ McGoon, M.D.⁴ Rich, S.⁵ Badesch, D.B.⁶ Groves, B.M.⁷ Tapson, V.F.⁸ Bourge, R.C.⁹ Brundage, B.H.¹⁰ Koerner, S.K.¹¹ Langleben, D.¹² Keller, C.A.¹³ Murali, S.¹⁴ Uretsky, B.F.¹⁵ Clayton, L.M.¹⁶ Jbsis, M.M.¹⁷ Blackburn Jr., S.D.¹⁸ Shortino, D.¹⁹ Crow, J.W.²⁰ more..

5
- 0035818316
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study
- DOI 10.1016/S0140-6736(01)06250-X
- R.N. Channick, G. Simonneau, O. Sitbon, I.M. Robbins, A. Frost, V.F. Tapson, D.B. Badesch, S. Roux, M. Rainisio, F. Bodin, and L.J. Rubin Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study Lancet 358 2001 1119 1123 (Pubitemid 32971843)
- (2001) Lancet , vol.358 , Issue.9288 , pp. 1119-1123
- Channick, R.N.¹ Simonneau, G.² Sitbon, O.³ Robbins, I.M.⁴ Frost, A.⁵ Tapson, V.F.⁶ Badesch, D.B.⁷ Roux, S.⁸ Rainisio, M.⁹ Bodin, F.¹⁰ Rubin, L.J.¹¹

6
- 26444534291
- Sildenafil citrate therapy for pulmonary arterial hypertension
- DOI 10.1056/NEJMoa050010
- N. Gali, H.A. Ghofrani, A. Torbicki, R.J. Barst, L.J. Rubin, D. Badesch, T. Fleming, T. Parpia, G. Burgess, A. Branzi, F. Grimminger, M. Kurzyna, G. Simonneau Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group Sildenafil citrate therapy for pulmonary arterial hypertension N Engl J Med 353 2005 2148 2157 (Pubitemid 41653106)
- (2005) New England Journal of Medicine , vol.353 , Issue.20 , pp. 2148-2157
- Galie, N.¹ Ghofrani, H.A.² Torbicki, A.³ Barst, R.J.⁴ Rubin, L.J.⁵ Badesch, D.⁶ Fleming, T.⁷ Parpia, T.⁸ Burgess, G.⁹ Branzi, A.¹⁰ Grimminger, F.¹¹ Kurzyna, M.¹² Simonneau, G.¹³

7
- 67649632034
- Diagnosis and assessment of pulmonary arterial hypertension
- D.B. Badesch, H.C. Champion, M.A. Sanchez, M.M. Hoeper, J.E. Loyd, A. Manes, M. McGoon, R. Naeije, H. Olschewski, R.J. Oudiz, and A. Torbicki Diagnosis and assessment of pulmonary arterial hypertension J Am Coll Cardiol 54 suppl 2009 S55 S66
- (2009) J Am Coll Cardiol , vol.54 , Issue.SUPPL.
- Badesch, D.B.¹ Champion, H.C.² Sanchez, M.A.³ Hoeper, M.M.⁴ Loyd, J.E.⁵ Manes, A.⁶ McGoon, M.⁷ Naeije, R.⁸ Olschewski, H.⁹ Oudiz, R.J.¹⁰ Torbicki, A.¹¹

8
- 65249161113
- Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension
- M.R. Fisher, P.R. Forfia, E. Chamera, T. Housten-Harris, H.C. Champion, R.E. Girgis, M.C. Corretti, and P.M. Hassoun Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension Am J Respir Crit Care Med 179 2009 615 621
- (2009) Am J Respir Crit Care Med , vol.179 , pp. 615-621
- Fisher, M.R.¹ Forfia, P.R.² Chamera, E.³ Housten-Harris, T.⁴ Champion, H.C.⁵ Girgis, R.E.⁶ Corretti, M.C.⁷ Hassoun, P.M.⁸

9
- 0037484589
- Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension a 1-year follow-up study
- DOI 10.1378/chest.124.1.247
- O. Sitbon, D.B. Badesch, R.N. Channick, A. Frost, I.M. Robbins, G. Simonneau, V.F. Tapson, and L.J. Rubin Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study Chest 124 2003 247 254 (Pubitemid 36851359)
- (2003) Chest , vol.124 , Issue.1 , pp. 247-254
- Sitbon, O.¹ Badesch, D.B.² Channick, R.N.³ Frost, A.⁴ Bobbins, I.M.⁵ Simonneau, G.⁶ Tapson, V.F.⁷ Rubin, L.J.⁸

10
- 6344240798
- Sustained symptomatic, functional, and hemodynamic benefit with the endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: A 1-year follow-up study
- DOI 10.1378/chest.126.4.1377
- D. Langleben, A.M. Hirsch, E. Shalit, L. Lesenko, and R.J. Barst Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study Chest 126 2004 1377 1381 (Pubitemid 39391276)
- (2004) Chest , vol.126 , Issue.4 , pp. 1377-1381
- Langleben, D.¹ Hirsch, A.M.² Shalit, E.³ Lesenko, L.⁴ Barst, R.J.⁵

11
- 33645243403
- Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension
- S. Provencher, O. Sitbon, M. Humbert, S. Cabrol, X. Jas, and G. Simonneau Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension Eur Heart J 27 2006 589 595
- (2006) Eur Heart J , vol.27 , pp. 589-595
- Provencher, S.¹ Sitbon, O.² Humbert, M.³ Cabrol, S.⁴ Jas, X.⁵ Simonneau, G.⁶

12
- 67649523052
- Tadalafil therapy for pulmonary arterial hypertension
- Pulmonary Arterial hypertension and Response to Tadalafil (PHIRST) Study Group
- N. Gali, B.H. Brundage, H.A. Ghofrani, R.J. Oudiz, G. Simonneau, Z. Safdar, S. Shapiro, R.J. White, M. Chan, A. Beardsworth, L. Frumkin, R.J. Barst Pulmonary Arterial hypertension and Response to Tadalafil (PHIRST) Study Group Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2009 2894 2903
- (2009) Circulation , vol.119 , pp. 2894-2903
- Gali, N.¹ Brundage, B.H.² Ghofrani, H.A.³ Oudiz, R.J.⁴ Simonneau, G.⁵ Safdar, Z.⁶ Shapiro, S.⁷ White, R.J.⁸ Chan, M.⁹ Beardsworth, A.¹⁰ Frumkin, L.¹¹ Barst, R.J.¹²

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.